About Andrew Van Dam
Andrew Van Dam of The Wall Street Journal previously worked at the AHCJ offices while earning his master’s degree at the Missouri School of Journalism.
Following in the footsteps of several other device manufacturers and medical interests, GE Healthcare is using UK libel laws, which some describe as “draconian,” to attempt to muzzle a Danish physician who helped discover links between the GE drug Omniscan and the debilitating and sometimes fatal disease nephrogenic systemic fibrosis.
ProPublica’s Jeff Gerth, who has been all over the Omniscan story for a while now, reports in The Sunday Times (and on ProPublica) on the lawsuit and the science, economics and politics behind it. The prominent Danish researcher, who noticed the link after a number of his patients came down with NSF, delivered a 15-minute PowerPoint presentation in Oxford in 2006 in which he referred to Omniscan as a potential “medical hurricane.” To date, GE has spent more than $600,000 fighting the claims with a libel suit.
Andrew Van Dam of The Wall Street Journal previously worked at the AHCJ offices while earning his master’s degree at the Missouri School of Journalism.
